Weekly Research Analysts’ Ratings Changes for Tango Therapeutics (TNGX)

A number of firms have modified their ratings and price targets on shares of Tango Therapeutics (NASDAQ: TNGX) recently:

• 6/25/2026 – Tango Therapeutics was upgraded by Jefferies Financial Group Inc. from “hold” to “buy”. They now have a $60.00 price target on the stock.
• 6/25/2026 – Tango Therapeutics was downgraded by Raymond James Financial, Inc. to “hold”.
• 6/12/2026 – Tango Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 6/9/2026 – Tango Therapeutics had its price target raised by HC Wainwright from $27.00 to $66.00. They now have a “buy” rating on the stock.
• 6/9/2026 – Tango Therapeutics had its price target raised by Canaccord Genuity Group Inc. from $30.00 to $42.00. They now have a “buy” rating on the stock.
• 6/8/2026 – Tango Therapeutics was given a new $36.00 price target by Mizuho.
• 6/8/2026 – Tango Therapeutics was given a new $35.00 price target by Wolfe Research. They now have an “outperform” rating on the stock.
• 6/8/2026 – Tango Therapeutics had its “buy” rating reaffirmed by B. Riley Financial, Inc..
• 6/8/2026 – Tango Therapeutics had its price target raised by Leerink Partners from $55.00 to $69.00. They now have an “outperform” rating on the stock.
• 6/8/2026 – Tango Therapeutics was upgraded by Wolfe Research from “peer perform” to “outperform”.
• 5/28/2026 – Tango Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 5/15/2026 – Tango Therapeutics had its price target raised by Mizuho from $20.00 to $30.00. They now have an “outperform” rating on the stock.
• 5/14/2026 – Tango Therapeutics was downgraded by Piper Sandler from “overweight” to “neutral”. They now have a $24.00 price target on the stock, up from $16.00.
• 5/14/2026 – Tango Therapeutics was given a new $55.00 price target by UBS Group AG.
• 5/14/2026 – Tango Therapeutics was downgraded by Jefferies Financial Group Inc. from “buy” to “hold”. They now have a $27.00 price target on the stock, up from $18.00.
• 5/14/2026 – Tango Therapeutics had its price target raised by Leerink Partners from $28.00 to $55.00. They now have an “outperform” rating on the stock.
• 5/14/2026 – Tango Therapeutics had its price target raised by Wedbush from $19.00 to $33.00. They now have an “outperform” rating on the stock.
• 5/11/2026 – Tango Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 4/27/2026 – Tango Therapeutics had its “buy” rating reaffirmed by Citigroup Inc..
• 4/27/2026 – Tango Therapeutics had its price target raised by Stifel Nicolaus from $24.00 to $40.00. They now have a “buy” rating on the stock.

Insider Transactions at Tango Therapeutics

In related news, insider Adam Crystal sold 38,460 shares of the business’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $25.00, for a total value of $961,500.00. Following the completion of the transaction, the insider owned 112,622 shares of the company’s stock, valued at $2,815,550. The trade was a 25.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 119,460 shares of company stock worth $2,724,600 over the last 90 days. Company insiders own 6.50% of the company’s stock.

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.